Efficacy of Sitagliptin on glycaemic control in drug naive patients with type 2 diabetes (STRICT-2).

Trial Profile

Efficacy of Sitagliptin on glycaemic control in drug naive patients with type 2 diabetes (STRICT-2).

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 May 2016

At a glance

  • Drugs Sitagliptin (Primary) ; Meglitinide; Metformin; Nateglinide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms STRICT-2
  • Most Recent Events

    • 18 Apr 2013 Planned end date changed from 30 Jun 2013 to 31 Aug 2013 as reported by University Hospital Medical Information Network - Japan.
    • 03 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 04 Apr 2012 Planned end date changed from 1 Mar 2012 to 1 Jun 2013 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top